Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Schoffelen, Annelot F ^a   Wensing, Annemarie M J ^a   Tempelman, Hugo A ^b   Geelen, Sibyl P M ^a   Hoepelman, Andy I M ^a   Barth, Roos E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NDLOVU CARE GROUP   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFANT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; RURAL AREA; SCHOOL CHILD; SOUTH AFRICA; TREATMENT FAILURE; VIREMIA; VIROLOGY; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; RURAL POPULATION; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84874829979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058526     Document Type: Article

References (32)

1. (2010) World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision.
2. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM, (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10: 155-166.
3. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, et al. (2009) Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 48: 115-122.
4. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids 20: 2355-2360.
5. Barth RE, Tempelman HA, Moraba R, Hoepelman AI, (2011) Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Res Treat 2011: 434375.
6. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, et al. (2010) Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis 10: 60-65.
7. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
8. McCutchan FE, (2006) Global epidemiology of HIV. Journal of medical virology 78Suppl 1: S7-S12.
9. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. The Lancet infectious diseases 11: 750-759.
10. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA, (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. Aids 23: 279-291.
11. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al. (2010) Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 11: 510-518.
12. Fox MP, Ive P, Long L, Maskew M, Sanne I, (2010) High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 500-506.
13. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. Aids 24: 1007-1012.
14. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, et al. (2011) Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 16: 853-861.
15. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. Aids 24: 1679-1687.
16. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, et al. (2011) Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. Journal of acquired immune deficiency syndromes 56: 333-339.
17. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N, (2012) Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Aids 26: 929-938.
18. (2011) The national antenatal sentinel HIV and syphilis prevalence survey, South Africa, 2010, National Department of Health.
19. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, et al. (2008) Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. Aids 22: 2210-2212.
20. Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, et al. (2008) Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 27: 977-984.
21. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, et al. (2011) Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J 30: 52-56.
22. Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DK, et al. (2012) Lopinavir/ritonavir Monotherapy After Virologic Failure of First-line Antiretroviral Therapy in Resource-limited Settings. Aids 26: 1345-1354.
23. (2011) DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 14, 2011.
24. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Jama 304: 321-333.
25. Cohen C, (2009) Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 10: 116-124.
26. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. The New England journal of medicine 366: 2380-2389.
27. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
28. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A, (2010) Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. Jama 304: 303-312.
29. Deeks SG, Barbour JD, Grant RM, Martin JN, (2002) Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. Aids 16: 201-207.
30. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD, (2008) Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. Aids 22: 1971-1977.
31. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, et al. (2009) Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. Aids 23: 697-700.
32. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, et al. (2011) Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. Aids 25: 1761-1769.